Cassava Sciences facing widening probe over short seller claims
By 
Jaclyn Jaeger2021-11-23T22:20:00
The SEC has reportedly launched an investigation into Cassava Sciences regarding allegations made against the clinical-stage biopharmaceutical company and its experimental Alzheimer’s drug by a law firm representing anonymous short sellers.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefCassava Sciences settles with SEC for $40M over skewed Alzheimer’s drug data
A former Alzheimer’s researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its former chief executive reaching a $40 million settlement with the Securities and Exchange Commission over allegedly misleading the public.
-
ArticleDOJ probe into shadowy underworld of short selling ‘long overdue’
A Department of Justice criminal investigation into illegal short selling is just the latest indication these schemes demand greater scrutiny that chief compliance officers and in-house counsel can no longer afford to ignore.
-
ArticleS&T AG orders Deloitte audit of short seller allegations
Austrian technology company S&T AG has ordered a forensic audit of its corporate structure and several recent acquisitions in response to allegations made by short seller Viceroy Research.
More from Regulatory Enforcement
-
ArticleTeledyne fined $1.5M for supplying obsolete parts to Navy
Teledyne will pay more than $1.5 million to settle allegations it supplied electronic parts to the Navy that deviated from specifications, a violation of the False Claims Act (FCA). But its cooperation with prosecutors earned it a credit, according to the U.S. Department of Justice (DOJ).
-
ArticleTungston rod importer pays $54.4M to settle DOJ tariff fraud allegations
An industrial products distributor has agreed to pay $54.4 million to settle allegations, first made by a whistleblower, that it evaded tariffs and violated the federal False Claims Act.
-
ArticleTariff evasion enforcement: The new FCPA
Companies that import goods into the United States will face heightened enforcement scrutiny for attempted acts of customs fraud, including tariff evasion, under the Trump administration. Thus, chief compliance officers and in-house counsel face a new kind of pressure to ensure they are mitigating risk in this area.